References
- 1. WHO. Global tuberculosis control 2010: TB facts [Internet]. 2011 [cited 2012 Mar 23]. Available from: http://www.who.int/tb/publications/global_report/2010/en/index.html
- 2. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, et al. Standard short-course chemotherapy for drug-resistant tuberculosis. JAMA. 2000; 283:2537-45.
- 3. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002; 62:2169-83.10.2165/00003495-200262150-00001
- 4. Holland DP, Hamilton CD, Weintrob AC, Engemann JJ, Fortenberry ER, Peloquin CA, et al. Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. Pharmacotherapy. 2009; 29:503-10.10.1592/phco.29.5.503
- 5. Mehta JB, Shantaveerapa H, Byrd RP, Morton SE, Fountain F, Roy TM. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest. 2001; 120: 1520-4.10.1378/chest.120.5.1520
- 6. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD, et al. Isoniazid, Rifampin, Ethambutol, and Pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIVinfected cohort of adults with tuberculosis from Botswana. Clin Infect Dis. 2009; 48:1685-94.10.1086/599040
- 7. Heysell SK, Moore JL, Keller SJ, Houpt ER. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis. 2010; 16:1546-53.10.3201/eid1610.100374
- 8. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Ch. 2006; 50:1170-7.10.1128/AAC.50.4.1170-1177.2006
- 9. Jittimanee S, Vorasingha J, Mad-asin W, Nateniyom S, Rienthong S, Varma JK. Tuberculosis in Thailand: epidemiology and program performance, 2001-2005. Int J Infect Dis. 2009; 13:436-42.10.1016/j.ijid.2008.07.025
- 10. Boonsarngsuk V, Tansirichaiya K, Kiatboonsri S. Thai drug-resistant tuberculosis predictive scores. Singapore Med J. 2009; 50:378-84.
- 11. Ministry of Public Health. The Thai guidelines for tuberculosis control in: Bureau of AIDS TB and STIs, (ed.). Office of National Buddhism Publisher: Bangkok. 2005.
- 12. Yoshiyama T, Supawitkul S, Kunyanone N, Riengthong D, Yanai H, Abe C, et al. Prevalence of drug-resistant tuberculosis in an HIV endemic area in northern Thailand. Int J Tuberc Lung D. 2001; 5: 32-9.
- 13. Akksilp S, Wattanaamornkiat W, Kittikraisak W, Nateniyom S, Rienthong S, Sirinak C, et al. Multidrugresistant TB and HIV in Thailand: overlapping, but not independently associated, risk factors. Southeast Asian J Trop Med Public Health. 2009; 40:1000-14.
- 14. Smith PJ, Van Dyk J, Fredericks A. Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma. Int J Tuberc Lung D. 1999; 3:S325-8.
- 15. Unsalan S, Sancar M, Bekce B, Clark PM, Karagoz T, Izzettin FV, et al. Therapeutic Monitoring of Isoniazid, Pyrazinamide and Rifampicin in tuberculosis patients using LC. Chromatographia. 2005; 61:595-8.10.1365/s10337-005-0549-0
- 16. Tappero JW, Bradford WZ, Agerton TB, Hopewell P, Reingold AL, Lockman S, et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis. 2005; 41: 461-9.10.1086/431984
- 17. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest. 1998; 113:1178-83.10.1378/chest.113.5.1178